UnitedHealth Group's Stock Plummets Amid Ongoing DOJ Investigation Into Medicare Billing Practices
On February 21, 2025, UnitedHealth Group Incorporated (NYSE: UNH) experienced a severe drop in stock value, plummeting by $36, or 7%, following a revealing report from the Wall Street Journal. The report disclosed that the U.S. Department of Justice (DOJ) has initiated a civil fraud inquiry into the company’s Medicare billing practices. This investigation is particularly focused on how UnitedHealth records diagnoses that lead to additional payments for its Medicare Advantage plans, which includes services associated with physician groups that the company owns.
The Wall Street Journal's piece titled "DOJ Investigates Medicare Billing Practices at UnitedHealth" has raised considerable alarms amongst investors and regulators alike. According to the article, healthcare professionals reported that UnitedHealth trained them to document revenue-producing diagnoses, many of which were labeled as obscure or irrelevant. Furthermore, the company allegedly utilized software that suggested conditions and provided bonuses for the consideration of these suggestions, a tactic the doctors found troubling.
As the market reacted to this unsettling news, over $33 billion in shareholder value was erased in just one trading day, reflecting the gravity of the situation. Following this, on February 24, 2025, Senator Chuck Grassley, who chairs the Senate Judiciary Committee, issued a demand to UnitedHealth’s CEO, Andrew Witty. Grassley sought to understand what measures the company has taken to review all diagnoses submitted to the Centers for Medicare & Medicaid Services (CMS) concerning its Medicare Advantage enrollees identified solely through the company’s in-home health risk assessments (HRAs). He pressed the company to identify any diagnoses that could be seen as obscure, irrelevant, or inaccurate and quantify inappropriate payments resultant from these actions.
Support for the investigation into UnitedHealth was bolstered by a previous report from the Department of Health and Human Services Office of Inspector General (HHS OIG) released in October 2024, which revealed that UnitedHealth had received more payments from CMS for diagnoses only recorded during HRAs and related chart reviews than any other Medicare Advantage Organization (MAO). The OIG noted a concerning trend where the absence of subsequent visits, procedures, tests, or supplies related to these diagnoses indicates a significant possibility of inaccuracies, leading to improper payments. This situation raises essential questions regarding whether enrollees have received adequate care for serious conditions that were reported only through HRAs.
"The apparent fraud, waste, and abuse at issue is simply unacceptable and harms not only Medicare beneficiaries but also American taxpayers," Senator Grassley expressed, highlighting the broader implications of the reported practices at UnitedHealth.
Reed Kathrein, a partner at Hagens Berman – a firm investigating these potential violations – noted concerns that UnitedHealth may have deceived its investors in relation to the legality of its Medicare Advantage practices and the revenues associated with them. He urged investors who have suffered considerable losses to come forward with their experiences.
Hagens Berman is currently calling for investors who purchased shares of UnitedHealth and experienced significant losses to share their stories, as the firm is compiling information regarding potential misconduct. Moreover, those with insider information have been encouraged to consider their options to aid in the investigation or to report through the SEC Whistleblower program, which offers rewards for original information provided.
Hagens Berman is no stranger to tackling complex litigation against corporations, boasting a successful history in holding entities accountable for wrongdoing. The firm represents a wide range of stakeholders including investors and whistleblowers who have perceived injustices impacting their rights or economic well-being. This case could add to its long record of advocating for corporate accountability, representing investors seeking justice in light of possibly misleading information that resulted in financial losses.
As the investigation unfolds, the focus on UnitedHealth Group's billing practices for Medicare services highlights the critical need for transparency and accuracy when dealing with federal healthcare programs. Investors and beneficiaries alike will be watching closely to see how this situation develops and what repercussions may follow for one of the largest healthcare providers in the United States.
The Wall Street Journal's piece titled "DOJ Investigates Medicare Billing Practices at UnitedHealth" has raised considerable alarms amongst investors and regulators alike. According to the article, healthcare professionals reported that UnitedHealth trained them to document revenue-producing diagnoses, many of which were labeled as obscure or irrelevant. Furthermore, the company allegedly utilized software that suggested conditions and provided bonuses for the consideration of these suggestions, a tactic the doctors found troubling.
As the market reacted to this unsettling news, over $33 billion in shareholder value was erased in just one trading day, reflecting the gravity of the situation. Following this, on February 24, 2025, Senator Chuck Grassley, who chairs the Senate Judiciary Committee, issued a demand to UnitedHealth’s CEO, Andrew Witty. Grassley sought to understand what measures the company has taken to review all diagnoses submitted to the Centers for Medicare & Medicaid Services (CMS) concerning its Medicare Advantage enrollees identified solely through the company’s in-home health risk assessments (HRAs). He pressed the company to identify any diagnoses that could be seen as obscure, irrelevant, or inaccurate and quantify inappropriate payments resultant from these actions.
Support for the investigation into UnitedHealth was bolstered by a previous report from the Department of Health and Human Services Office of Inspector General (HHS OIG) released in October 2024, which revealed that UnitedHealth had received more payments from CMS for diagnoses only recorded during HRAs and related chart reviews than any other Medicare Advantage Organization (MAO). The OIG noted a concerning trend where the absence of subsequent visits, procedures, tests, or supplies related to these diagnoses indicates a significant possibility of inaccuracies, leading to improper payments. This situation raises essential questions regarding whether enrollees have received adequate care for serious conditions that were reported only through HRAs.
"The apparent fraud, waste, and abuse at issue is simply unacceptable and harms not only Medicare beneficiaries but also American taxpayers," Senator Grassley expressed, highlighting the broader implications of the reported practices at UnitedHealth.
Reed Kathrein, a partner at Hagens Berman – a firm investigating these potential violations – noted concerns that UnitedHealth may have deceived its investors in relation to the legality of its Medicare Advantage practices and the revenues associated with them. He urged investors who have suffered considerable losses to come forward with their experiences.
Hagens Berman is currently calling for investors who purchased shares of UnitedHealth and experienced significant losses to share their stories, as the firm is compiling information regarding potential misconduct. Moreover, those with insider information have been encouraged to consider their options to aid in the investigation or to report through the SEC Whistleblower program, which offers rewards for original information provided.
Hagens Berman is no stranger to tackling complex litigation against corporations, boasting a successful history in holding entities accountable for wrongdoing. The firm represents a wide range of stakeholders including investors and whistleblowers who have perceived injustices impacting their rights or economic well-being. This case could add to its long record of advocating for corporate accountability, representing investors seeking justice in light of possibly misleading information that resulted in financial losses.
As the investigation unfolds, the focus on UnitedHealth Group's billing practices for Medicare services highlights the critical need for transparency and accuracy when dealing with federal healthcare programs. Investors and beneficiaries alike will be watching closely to see how this situation develops and what repercussions may follow for one of the largest healthcare providers in the United States.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.